Abstract:
The present invention relates to a pharmaceutical composition and a health food containing eleutheroside E for preventing or treating insulin resistance or insulin resistance-related diseases. The compositions show significant effects in blood glucose regulation, glucose tolerance improvement, insulin resistance improvement, and insulin reduction in blood, thereby preventing and treating insulin resistance or insulin resistance-related diseases. [Reference numerals] (AA,DD) Diabetes group;(BB) Diabetes group +E. senticosus;(CC) Diabetes group + Eleutherosld E;(EE) Diabetes group +E. senticosus;(FF) Diabetes group +Eleutheroside E
Abstract:
PURPOSE: A composition containing isoliquiritigenin or salt thereof for preventing and treating obesity is provided to suppress adipocytes and to reduce body fat. CONSTITUTION: A composition for preventing and treating obesity contains 0.1-10 wt% of isoliquiritigenin or salt thereof as an active ingredient. A food composition for preventing and treating obesity contains isoliquiritigenin or salt thereof as an active ingredient. A method for preparing and treating obesity comprises a step of adding isoliquiritigenin or salt thereof. The daily dose is 0.0001-100 mg/kg.
Abstract:
PURPOSE: A composition for suppressing obesity containing Erythronium japonicum extract or organic solvent fraction thereof is provided to effectively suppress differentiation of adipocyte. CONSTITUTION: A composition for suppressing obesity contains Erythronium japonicum extract or organic solvent fraction thereof as an active ingredient. The Erythronium japonicum extract is ethanol or spirit extract. The organic solvent fraction is chloroform or ethylacetate fraction. The Erythronium japonicum extract is 80% ethanol extract. A composition for suppressing obesity further contains Heloniopsis orientalis extract and acetate fraction thereof.
Abstract:
Psoralea coyliflia extracts with high estrogenic activity or a composition containing active components separated from the Psoralea corylifolia extracts are provided to replace a hormone replacement therapy which administers estrogen by using a natural product. A method for separating active components from Psoralea corylifolia extracts comprises the steps of: (i) extracting Psoralea corylifolia alcohol solvent extract with dichloromethane; (ii) performing silica gel column chromatography that makes the dichloromethane/methanol solution in Psoralea corylifolia dichloromethane extracts mobile to obtain the first fraction or the eleventh fraction; and (iii) performing silica gel column chromatography that makes normal hexane/ethylacetate in the third fraction among 11 fractions mobile to obtain 10 fractions from 3-1 to 3-10, and vacuum concentrating 3-2 fraction to obtain bakuchiol.
Abstract:
본 발명은 들깨박 추출물을 유효성분으로 함유하는 인지기능장애 예방 및 개선용 조성물을 제공한다. 특히 본 발명에 따른 조성물은 체내 지질과산화물의 축적을 억제하고, 동시에 항산화효소의 활성을 증가시키는 효과가 있으며, 또한 신경전달체계에 있어서 매우 중요한 역할을 수행하는 아세틸콜린에스터라아제의 활성을 저하하는 방법으로 치매 등의 인지기능장애를 예방하고, 동시에 개선시키는 효과가 우수하므로 다양한 건강보조식품 내지는 약제학적 조성물로서 제공되어질 수 있다. 들깨박, 인지기능장애, 알츠하이머, 치매
Abstract:
본 발명은 세사미놀 배당체 또는 이를 포함하는 참깨 추출물을 유효성분으로 하는 치매 예방 및 치료용 조성물에 관한 것이다. 보다 구체적으로, 본 발명은 세사미놀 배당체 또는 이를 포함하는 참깨 추출물을 유효성분으로 하는 치매 예방 및 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 세사미놀 배당체 또는 참깨 추출물을 유효성분으로 하는 조성물은 치매의 병인과 관련이 깊은 산화적 스트레스를 억제하여 기억력 및 학습능을 증강시킴으로써 치매를 예방 또는 치료하는 효과가 있다.